Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Mo Wu, Wei Huang, Nan Yang, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 112
Peptide-drug conjugates: A new paradigm for targeted cancer therapy
Mo Wang, Jiawei Liu, Mingjing Xia, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116119-116119
Closed Access | Times Cited: 29
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic
Syed Faheem Askari Rizvi, Lin‐Jie Zhang, Haixia Zhang, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 2, pp. 309-334
Open Access | Times Cited: 17
Development of antibody‐drug conjugates in cancer: Overview and prospects
Dan‐Yun Ruan, Hao‐Xiang Wu, Qi Meng, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 3-22
Open Access | Times Cited: 25
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs
Qi Zhao, Hong Zong, Pingping Zhu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Engineering peptide drug therapeutics through chemical conjugation and implication in clinics
Syed Faheem Askari Rizvi, Haixia Zhang, Quan Fang
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2420-2471
Closed Access | Times Cited: 11
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Engineered Antibodies as Cancer Radiotheranostics
Zhen-Ni Wei, Bingyu Li, Xuejun Wen, et al.
Advanced Science (2024) Vol. 11, Iss. 30
Open Access | Times Cited: 8
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
Longkun Wang, Chunqian Zhao, Lu Lu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4646-4646
Open Access | Times Cited: 18
Lenvatinib resistance mechanism and potential ways to conquer
Wentao Bo, Yan Chen
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Tuneable redox-responsive albumin-hitchhiking drug delivery to tumours for cancer treatment
Shiwei Fu, Ajay Zheng, Lukun Wang, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 27, pp. 6563-6569
Open Access | Times Cited: 5
Innovative design concepts in tumor-targeting peptide-drug conjugates: Insights into emerging applications
Ruirong Tan, Zhenya Yang, Xie Jun, et al.
Chinese Medical Journal (2025)
Open Access
Design and synthesis of TH19P01-Camptothecin based hybrid peptides inducing effective anticancer responses on sortilin positive cancer cells
Yajie Li, Chang-Bo Fang, Shu‐shu Wang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117869-117869
Closed Access | Times Cited: 4
Multiomics analysis reveals the involvement of NET1 in tumour immune regulation and malignant progression
Jian Pang, Xiaoyan Huang, Ya Gao, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Acid‐Triggered Cascaded Responsive Supramolecular Peptide Alleviates Myocardial Ischemia‒Reperfusion Injury by Restoring Redox Homeostasis and Protecting Mitochondrial Function
Xu Liao, Min Tang, Jiejing Li, et al.
Advanced Healthcare Materials (2025)
Closed Access
The validation and clinical bioanalysis of the Bicycle® Toxin Conjugate zelenectide pevedotin in human plasma
Joseph Tweed, Fern Adams-Dam, Justin Bader, et al.
Bioanalysis (2025), pp. 1-9
Closed Access
Development of Novel Peptide-Based Radiotracers for Detecting FGL1 Expression in Tumors
Yue Xu, Jinyuan Zhang, Donghui Pan, et al.
Molecular Pharmaceutics (2025)
Closed Access
Evaluation of the Efficacy of Proline Rich VPPPVPPRRR Peptide (VPP) in MCF-7 Cells
Ziyşan Buse Yaralı Çevik, Berk Buğra Sönmez, Ozan Karaman
International Journal of Peptide Research and Therapeutics (2025) Vol. 31, Iss. 3
Closed Access
Recent Advances in Smart Linkage Strategies for Developing Drug Conjugates for Targeted Delivery
Jie Zhang, Zeyu Yang, Yu Liu, et al.
Topics in Current Chemistry (2025) Vol. 383, Iss. 2
Closed Access
Development of a 18F-Labeled Bicyclic Peptide Targeting EphA2 for Molecular Imaging of PSMA-Negative Prostate Cancer
Qianqian Gan, Kai Cui, Qi Cao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14623-14632
Closed Access | Times Cited: 10
Discovery of novel HER2 targeting peptide-camptothecin conjugates with effective suppression for selective cancer treatment
Hanyu Wu, Yunxiao Liu, Jiaqi Zhou, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107371-107371
Closed Access | Times Cited: 3
Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
Valentina Rossi, Alessandra Turati, Antonio Rosato, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
New Transferrin Receptor-Targeted Peptide–Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity
Jiale Yu, Xiaoxia Mao, Xue Yang, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1758-1758
Open Access | Times Cited: 2
Peptides as innovative strategies to combat drug resistance in cancer therapy
Henry Lamb, Aurélie H. Benfield, Sónia Troeira Henriques
Drug Discovery Today (2024) Vol. 29, Iss. 12, pp. 104206-104206
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top